Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.137, Iss.2, 2013-01, pp. : 397-406

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tamoxifen sensitivity and estrogen receptor mRNA levels

By Span P.

Breast Cancer Research and Treatment, Vol. 121, Iss. 3, 2010-06 ,pp. : 793-794

Springer Publishing Company

Access to resources Recommend Favorite

Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway

Oncology Reports, Vol. 31, Iss. 3, 2014-01 ,pp. : 1175-1182

Spandidos Publications

Access to resources Recommend Favorite

Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway

Molecular Medicine Reports, Vol. 11, Iss. 2, 2015-01 ,pp. : 1516-1522

Spandidos Publications

Access to resources Recommend Favorite

Low levels of estrogen receptor- protein predict resistance to tamoxifen

By Lovergine Silvia Masciullo Valeria

The Women's Oncology Review, Vol. 5, Iss. 1, 2005-03 ,pp. : 17-18

Informa Healthcare

Access to resources Recommend Favorite

Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α

International Journal of Oncology, Vol. 45, Iss. 5, 2014-01 ,pp. : 2167-2175

Spandidos Publications

Access to resources Recommend Favorite